Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARNEST trial of Entyvio for chronic or recurrent pouchitis
NL-OMON47815Phase 4Active, not recruiting
- Sponsor
- Takeda
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pouchitis comparing Vedolizumab IV plus ciprofloxacin with Placebo IV plus ciprofloxacin (2 arms). Primary endpoint: Clinically relevant remission at Week 14. Started Dec 2016; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
pouchitis
Beyond the preview
Go deeper on NL-OMON47815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47815.